Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 82

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 82
---
 patent. Under
either the previous or current system, third parties will be allowed to submit prior art prior to the issuance of a patent by the United
States Patent and Trademark Office, and may become involved in opposition, derivation, reexamination, inter-partes review or interference
proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding
or litigation could reduce the scope of, or invalidate, our patent rights, which could adversely affect our competitive position with
respect to third parties.

Our commercial success depends, in part, upon our not infringing intellectual property rights owned by others.

Although we believe that we
have proprietary platforms for our technologies and product candidates, we cannot determine with certainty whether any existing third
party patents or the issuance of any third party patents in the future would require us to alter our technology, obtain licenses or cease
certain activities. We may become subject to claims by third parties that our technology infringes their intellectual property rights,
in which case we will have no option other than to defend the allegation, which may be possible to resolve through negotiation or which
might result in court proceedings. An adverse outcome in any of these circumstances is that we might be subject to significant liabilities,
be required to cease using a technology or to pay license fees (both prospectively and retrospectively); and may be subject to the payment
of significant damages. We could incur substantial costs in any litigation or other proceedings relating to patent rights, even if it
is resolved in our favor. If the proceedings occur in the United States, it is likely that we will be responsible for our own legal costs,
no matter the outcome of the litigation. In contrast, in the United Kingdom, the losing party typically is ordered to pay the winning
party’s costs, although it is rare to have a complete recovery of all costs from the losing side. Some of our competitors may be
able to sustain the costs of complex litigation more effectively or for a longer time than we can because of their substantially greater
resources. In addition, uncertainties or threatened or actual disputes relating to any patent, patent application or other intellectual
property right (including confidential information) could have a material adverse effect on our ability to market a product, enter into
collaborations in respect of the affected products, or raise additional funds.

The policing of unauthorized
use of our patented technologies and product candidates is difficult and expensive. There can be no assurance that the steps we take will
prevent misappropriation of